Filing Flows › Allogene Therapeutics (ALLO) › Stock forecast & fair value
Allogene Therapeutics (ALLO) stock forecast and price target
Allogene Therapeutics (ALLO) trades at $1.04. 9 analysts' median price target is $9.00 (+765%), from $4.00 to $14.00.
Allogene Therapeutics' latest quarter
Allogene Therapeutics, Q2 2026: revenue $4.6M, net loss $42.7M, operating cash flow −$32.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for ALLO stock?
The median of 9 analysts' 12-month targets is $9.00, +765% from $1.04; the range is $4.00 to $14.00. The average rating is strong buy.
Does Allogene Therapeutics usually beat earnings estimates?
It beat the consensus EPS estimate in 60% of the quarters on record.
Is ALLO stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.